AAM Sees Boon From Biden Order And CMS Biosimilar Action
US Generics And Biosimilars Industry Association Welcomes Latest Developments
Executive Summary
The US Association for Accessible Medicines has welcomed an executive order from president Joe Biden aimed at lowering prescription drug costs, shortly after the AAM’s Biosimilars Council praised payment changes for biosimilars made by the Centers for Medicare & Medicaid Services.
You may also be interested in...
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks about how the firm is gearing up to launch three key products.
Shared Savings Legislation Could Increase Medicare Biosimilar Access
Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks to Generics Bulletin about how the firm is gearing up to launch three key products.